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Reperfusion injury after hepatic ischemia is asso-
ciated with infl  ammation and ongoing necrosis 
that is amplifi  ed by deletion of the adenosine 
A2A receptor (A2AR) (1). The activity of most 
infl  ammatory cells, including but not limited 
to macrophages, monocytes, T   lymphocytes, 
platelets, and polymorphonuclear leukocytes, is in-
hibited by the activation of the antiinfl  ammatory 
Gs-coupled A2AR, resulting in reduced pro-
infl  ammatory cytokine production and dimin-
ished endothelial adhesion molecule expression 
(2–7). Accumulating evidence   suggests that 
hepatic reperfusion injury is triggered by lym-
phocyte activation (1) and that the activation of 
A2ARs on bone marrow–derived cells mediates 
liver protection (8). These fi  ndings, and   studies 
establishing that the activation of the A2AR on 
CD4+ T cells inhibits TCR-mediated IFN-γ pro-
duction in vitro (3), suggest that treatment with 
the selective A2AR agonist 4-{3-[6-Amino-9-
(5-ethylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-
2-yl)-9H-purin-2-yl]-prop-2-ynyl}-cyclohex
anecarboxylic acid methyl ester (ATL146e) may 
mediate protection from hepatic ischemia reper-
fusion injury (IRI) by inhibiting the activation 
of CD4+ T lymphocytes. However, the rapidity 
of reperfusion injury is not consistent with the 
timeframe required for activation and diff  eren-
tiation of conventional CD4+ T cell responses, 
suggesting it is mediated by a rapidly activated 
T cell subset.
The majority of mouse CD4+NK1.1+ NKT 
cells express the invariant TCR, Vα14Jα18, and 
are dependent on CD1d for positive   selection 
in the thymus and subsequent activation in the 
periphery (9, 10). CD1d is expressed by hepato-
cytes, gut epithelial cells, and APCs and presents 
either self-glycolipid, such as isoglobotrihexo-
sylceramide (11), or foreign glycolipid, such as 
the marine sponge–derived α-galactosylceramide 
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Ischemia reperfusion injury results from tissue damage during ischemia and ongoing in-
fl  ammation and injury during reperfusion. Liver reperfusion injury is reduced by lymphocyte 
depletion or activation of adenosine A2A receptors (A2ARs) with the selective agonist 4-
{3-[6-amino-9-(5-ethylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-
prop-2-ynyl}-cyclohexanecarboxylic acid methyl ester (ATL146e). We show that NKT cells 
are stimulated to produce interferon (IFN)-𝗄 by 2 h after the initiation of reperfusion, and 
the use of antibodies to deplete NK1.1-positive cells (NK and NKT) or to block CD1d-
mediated glycolipid presentation to NKT cells replicates, but is not additive to, the protec-
tion afforded by ATL146e, as assessed by serum alanine aminotransferase elevation, 
histological necrosis, neutrophil accumulation, and serum IFN-𝗄 elevation. Reduced reper-
fusion injury observed in RAG-1 knockout (KO) mice is restored to the wild-type (WT) level 
by adoptive transfer of NKT cells purifi  ed from WT or A2AR KO mice but not IFN-𝗄 KO 
mice. Additionally, animals with transferred A2AR−/− NKT cells are not protected from 
hepatic reperfusion injury by ATL146e. In vitro, ATL146e potently inhibits both anti-CD3 
and 𝗂-galactosylceramide–triggered production of IFN-𝗄 by NKT cells. These fi  ndings 
suggest that hepatic reperfusion injury is initiated by the CD1d-dependent activation of 
NKT cells, and the activation of these cells is inhibited by A2AR activation.
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(α-Gal-Cer) (12), to NKT cells. The rapid release of IFN-γ 
or IL-4 after activation of invariant NKT (iNKT) cells by 
CD1d glycolipid presentation to TCRs has been attributed 
to preformed cytokine transcripts (13). Although NKT cells 
compose only 0.1–3% of the T lymphocyte population in 
blood and spleen, in the mouse liver NKT cells account for as 
much as 30% of the total lymphocyte population and as much 
as 50% of total αβ TCR+ T cells (14). The high abundance of 
NKT cells in the liver and their rapid response to activation 
suggests that they might play a role in hepatic reper  fusion 
injury. In this study we sought to better characterize the 
eff  ects of hepatic reperfusion injury and A2AR activation on 
NKT cell activity. We show that NKT cells are involved in the 
pathogenesis of hepatic IRI and that they comprise a subset 
of CD4+ T lymphocytes through which ATL146e mediates 
liver protection.
RESULTS
Blockade of NKT cell activation reduces hepatic IRI
Clamping the hepatic triad of WT C57BL/6 mice for vari-
ous times and reperfusing for 24 h induces considerable 
time-dependent liver damage. Deletion of the A2AR exacer-
bates reperfusion injury, implicating endogenous adenosine 
in liver protection (1). Protection, as manifested by reduced 
serum alanine aminotransferase (ALT) levels and lessened 
necrotic area, is produced in WT mice by administration of 
the synthetic A2AR agonist ATL146e immediately after the 
initiation of reperfusion. Serum ALT levels in ATL146e-
treated mice are reduced by  58% versus vehicle-treated 
controls, and the necrotic area is 6.1 ± 0.8% as opposed to 
79.3 ± 3% in vehicle-treated animals (lightly stained areas 
are necrotic; Fig. 1). RAG-1 KO mice, which lack mature 
lymphocytes, also exhibit reduced ALT and necrosis when 
compared with age- and sex-matched WT C57BL/6 mice 
(63% reduction in serum ALT levels and 4.5 ± 1% reduced 
necrotic area; Fig. 1). ATL146e treatment of C57BL/6 mice 
and lymphocyte defi  ciency in RAG-1 KO mice result in 
similar reductions in serum ALT levels and liver necrosis. To 
test the hypothesis that NKT cell activity contributes to liver 
IRI, we examined the eff   ects of depleting these cells or 
blocking their CD1d-dependent activation. Treatment of 
WT C57BL/6 mice with anti-NK1.1 (PK136) 2 d before 
liver IRI substantially depletes NKT and NK cells in the 
spleen and liver as assessed by FACS analysis (Fig. 2 A) while 
leaving conventional CD4+ and CD8+ T cell number intact 
(not depicted). This depletion results in  60% reduction in 
serum ALT levels 24 h after reperfusion and a large reduc-
tion in necrotic area (8.2 ± 2% necrotic area; Fig. 2 B). The 
administration of a CD1d-blocking antibody 24 h before 
  injury elicits a similar reduction in serum ALT levels and 
  necrosis as does PK136 treatment (Fig. 2 C). Co-treatment 
with either antibody in conjunction with ATL146e aff  ords 
no additional protection beyond that achieved by NK1.1 
cell depletion or CD1d blockade alone. These results are 
consistent with CD1d-restricted NKT cell involvement in 
hepatic IRI.
The adoptive transfer of NKT cells restores liver injury 
to RAG-1 KO mice
Adoptive transfer of CD4+NK1.1+ NKT cells collected 
from the spleens of WT C57BL/6 mice into RAG-1 KO 
mice 4 d before surgery was found to reconstitute hepatic 
  injury after IRI. This eff  ect is cell number–dependent, with 
WT levels of injury restored by the adoptive transfer of 
250,000 NKT cells and intermediate injury by 150,000 cells 
(Fig. 3 A). Approximately 75% of the CD4+NK1.1+ cells 
transferred expressed the invariant Vα14Jα18 TCR, as indi-
cated by binding of an α-Gal-Cer–loaded CD1d tetramer 
(not depicted), and FACS analysis confi  rmed that the adop-
tively transferred NKT cells reach the livers of reconstituted 
animals (Fig. 3 B). Although the adoptive transfer of WT 
NKT cells reconstitutes liver injury after IRI, the transfer of 
250,000 NKT cells collected from IFN-γ KO mice fails to 
do so; serum ALT levels are not signifi  cantly diff  erent from 
RAG-1 KO controls (Fig. 3 C). The adoptive transfer of 
250,000 NKT cells from A2AR KO mice restores injury to 
RAG-1 KO mice to an extent similar to transfer of WT 
Figure 1.  Protection from hepatic IRI by A2AR activation or lympho-
cyte defi  ciency. WT or Rag-1 KO C57BL/6 mice were subjected to 72 min 
of hepatic ischemia followed by 24 h of reperfusion, or sham surgeries. 
Immediately after the initiation of reperfusion, animals received ATL146e 
or vehicle control. Animals were killed by cervical dislocation after 24 h 
of reperfusion, blood was collected via retro-orbital bleed, and serum ALT 
was measured. Additionally, livers were perfused, and left liver lobes were 
collected and placed immediately into 4% paraformaldehyde. Necrosis 
was measured via H&E staining. Data shown are from three independent 
experiments (n = 9); error bars indicate SEM. *, P < 0.01 versus C57BL/6 
vehicle control as assessed by one-way ANOVA, followed by Dunnett’s 
multiple comparison test. H&E staining shown is representative of fi  ve 
10× fi  elds of view photographed for each of nine animals in three 
  independent experiments. Bar, 200 μm.JEM VOL. 203, November 27, 2006  2641
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NKT cells, but treatment with ATL146e protects from 
tissue damage only when WT cells are transferred; A2AR 
deletion on the NKT cells abolishes the eff  ect of agonist 
administration (Fig. 3 D). These fi  ndings suggest that NKT 
cells play a pivotal role in hepatic reperfusion injury, that 
this activity is dependent on the production of IFN-γ, and 
that the protection elicited by ATL146e treatment is depen-
dent on the expression of functional A2ARs on NKT cells.
IFN-𝗄 production and neutrophil accumulation after 
hepatic IRI is dependent on NKT cell activation
NKT cells isolated from postischemic mouse liver and liver- 
draining lymph nodes after 2 h of reperfusion display an 
activated phenotype, as indicated by an increase in  intracellular 
IFN-γ expression as compared with sham surgery controls. 
Treatment with ATL146e at the initiation of reperfusion sig-
nifi  cantly inhibits this activation. (Fig. 4 A). Because activated 
Figure 2.  Involvement of NKT cells in the pathogenesis of hepatic IRI. 
WT C57BL/6 mice were subjected to hepatic IRI or sham surgeries. Imme-
diately after the initiation of reperfusion, select animals received ATL146e 
or vehicle control. Additionally, animals received either a single i.p. injec-
tion of 200 μg PK136 or vehicle control 2 d before surgery (A and B) or 
a single i.p. injection of 300 μg of a CD1d blocking antibody or vehicle 
control 24 h before surgery (C). Animals were killed by cervical dislocation 
after 24 h of reperfusion, blood was collected via retro-orbital bleed, and 
serum ALT was measured. Livers were perfused, and left liver lobes were 
collected and placed immediately into 4% paraformaldehyde. Necrosis 
was measured via H&E staining. Cell depletion by PK136 was assessed via 
the FACS analysis of spleen and liver tissue harvested from PK136-treated 
mice after 24 h of reperfusion (A). Numbers indicate the percentages of 
CD3+CD1d tetramer+ (A, top) and CD45+DX5+ (A, bottom) cells in the 
boxed regions. Data shown are from three independent experiments (n = 9); 
error bars indicate SEM. *, P < 0.01 versus vehicle control as assessed by 
one-way ANOVA, followed by Dunnett’s multiple comparison test. H&E 
staining shown is representative of fi  ve 10× fi  elds of view photographed 
for each of nine animals in three independent experiments. Bar, 200 μm.2642  CD1D-RESTRICTED NKT CELLS AND REPERFUSION INJURY | Lappas et al.
NKT cells are known to release large amounts of IFN-γ and 
to stimulate IFN-γ release from bystander cells, we also ex-
amined plasma levels of IFN-γ 24 h after reperfusion injury. 
IRI substantially increased plasma IFN-γ concentrations at 
24 h, and treatment with ATL146e, PK136, or anti-CD1d 
antibodies all diminished this elevation to a similar extent 
(Fig. 4 B). The large accumulation of neutrophils that is ob-
served in the postischemic liver of WT C57BL/6 mice after 
24 h of reperfusion was also reduced substantially in RAG-1 
KO mice and to a similar extent in mice pretreated with 
PK136 or CD1d blocking antibody (Fig. 4 C). These fi  nd-
ings indicate that NKT cells are activated rapidly after the 
initiation of reperfusion, that ATL146e inhibits this activa-
tion, and that the large accumulation of both serum IFN-γ 
and hepatic neutrophils that occurs 24 h after liver reperfu-
sion is secondary to NKT cell activation.
ATL146e treatment inhibits IFN-𝗄 production by purifi  ed 
NKT cells
CD4+NK1.1+ NKT cells purifi   ed from spleens of WT 
C57BL/6 mice were activated on immobilized anti-CD3 mAb 
to stimulate the release of IFN-γ, as measured in cell super-
natants after 24 h of incubation. TCR-stimulated IFN-γ pro-
duction is inhibited by  73% by coincubation with 100 nM 
ATL146e (Fig. 5 A). iNKT cells in a mixed splenocyte culture 
were selectively activated in a dose-dependent manner by α-Gal-
Cer, and this activation stimulated the production of IFN-γ, 
which is inhibited competently by 100 nM ATL146e (Fig. 5 
B). The iNKT-mediated production of IFN-γ that is stimu-
lated by 1 μM α -Gal-Cer is inhibited by ATL146e with an 
EC50 value of 0.58 nM. The addition of 100 nM of the selec-
tive A2AR antagonist 4-(2-[7-amino-2-[2-furyl][1,2,4]triazolo
[2,3-a][1,3,5]triazin-5-yl-amino]ethyl)phenol (ZM241385) 
causes a right shift in the ATL146e dose-response curve that 
is characteristic of competitive A2AR blockade (Fig. 5 C).   
Co-treatment with 1 μM of the charged sulfonic acid   adenosine 
receptor antagonist 8-sulfophenyltheophylline (8-SPT) also 
blocks the inhibitory eff  ects of ATL146e on α-Gal-Cer–
  mediated IFN-γ production by a mixed splenocyte culture 
(Fig. 5 D). Because 8-SPT cannot cross the cell membrane, 
this indicates that the eff  ects of ATL146e are mediated by 
A2ARs expressed on the cell surface. It is possible that some of 
the IFN-γ produced by mixed splenocytes might be derived 
from the transactivation of conventional lymphocytes or NK 
cells secondary to NKT cell activation. To eliminate these 
possible sources of IFN-γ, we also measured the release of 
IFN-γ from purifi  ed CD4+ NK1.1+ NKT cells activated with 
1 μM α-Gal-Cer in the presence of lymphocyte-defi  cient, 
NK cell–depleted RAG-1 KO splenocytes as a source of APCs. 
IFN-γ derived from NKT cell activation in this experiment 
was reduced 93% by 100 nM ATL146e, and this eff  ect was 
blocked by co-treatment with 100 nM ZM241385 (Fig. 5 E). 
These fi  ndings demonstrate for the fi  rst time that the produc-
tion of IFN-γ by NKT cells in response to CD1d-dependent 
activation is inhibited by activation of the A2AR. Blockade of 
ATL146e activity by ZM241385 and 8-SPT indicate that this 
activity is dependent on functional cell surface expression of 
the A2AR.
D  I  S  C  U  S  S  I  O  N 
IRI is characterized by initial tissue damage during the isch-
emic period followed by progressive injury during the reper-
fusion period. Reperfusion is a trigger for the generation of 
reactive oxygen species (ROS), release of cytokines, induc-
tion of adhesion molecules on vascular endothelial cells, and 
the adhesion and extravasation of leukocytes into postisch-
emic tissue. We and others have found that treatment with 
agonists of A2ARs or depletion of CD4+ lymphocytes eff  ec-
tively reduces infl  ammatory processes and the amount of 
tissue damage that occurs during reperfusion (8, 15–18). Of 
the total tissue necrosis that occurs in models of heart, kid-
ney, skin, and liver IRI, 30–75% of the tissue injury occurs 
during reperfusion and can be prevented by treatment with 
A2AR agonists (19). In this study we show that the activation 
of NKT cells by a CD1d-dependent mechanism plays a 
central role in initiating the infl  ammatory cascade responsible 
for reperfusion injury in the liver and that these cells are key 
Figure 3.  Adoptive transfer of NKT cells restores injury to RAG-1 
KO mice. WT or RAG-1 KO C57BL/6 mice were subjected to 72 min of 
hepatic IRI or sham surgeries. Immediately after the initiation of reper-
fusion, select animals received ATL146e or vehicle control. Purifi  ed 
CD4+NK1.1+ T cells from WT (A and B), IFN-γ KO (C), or A2AR KO (D) 
C57BL/6 mice were adoptively transferred into select RAG-1 KO mice 4 d 
before hepatic IRI. Successful reconstitution of CD4+NK1.1+ T cells into 
the livers of recipient animals was confi  rmed by FACS analysis of leuko-
cytes collected from liver tissue after 24 h of reperfusion; numbers indi-
cate the percentages of cells in each quadrant (B). Animals were killed by 
cervical dislocation after 24 h of reperfusion, blood was collected via 
retro-orbital bleed, and serum ALT was measured. Data shown are from 
three independent experiments (n = 9); error bars indicate SEM. *, P < 0.01 
versus WT C57BL/6 control as assessed by one-way ANOVA, followed 
by Dunnett’s multiple comparison test.JEM VOL. 203, November 27, 2006  2643
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targets of A2AR agonists (Fig. 6). Based on adoptive transfer 
experiments of NKT cells into RAG-1 KO mice, we show 
that NKT cells are suffi   cient to cause reperfusion injury even 
in the absence of other lymphocytes. Additionally, we show 
that the activity of NKT cells to mediate liver reperfusion 
  injury is dependent on the production of IFN-γ and that 
  activation of the Gs-coupled A2AR markedly inhibits the 
production of IFN-γ by NKT cells both in vitro and in vivo. 
Although cAMP elevation has been found to inhibit CD8+ 
NKT cell cytotoxic activity (20), the current study is the fi  rst 
to demonstrate inhibition of CD4+ NKT cell cytokine pro-
duction by a cAMP-elevating A2AR agonist.
Liver-resident NKT cells are known to play a role in tu-
mor surveillance and protection from hepatitis B viral infec-
tion (12, 21–23). The selective activation of NKT cells with 
i.p. or i.v. injection of α-Gal-Cer results in an elevation of 
serum IFN-γ and ALT levels and induces liver tissue damage 
(24). The involvement of TCR activation in reperfusion in-
jury is supported by previous work demonstrating that block-
ade of TCR signaling with cyclosporine treatment reduces 
hepatic reperfusion injury (25, 26). Additionally, CD1d−/− 
mice demonstrate considerably reduced liver reperfusion in-
jury as compared with WT controls (27). The activity of 
CD1d to activate NKT cells during reperfusion implicates 
host glycolipid antigens, possibly derived or released from 
necrotic cells, in the rapid activation of the innate immune 
system. When activated, NKT cells rapidly release large 
amounts of both IL-4 and IFN-γ, which has been demon-
strated to act via a STAT-1–dependent mechanism to acti-
vate Kupff  er cells, as well as hepatocytes and sinusoidal 
endothelial cells, to produce chemokines and up-regulate ad-
hesion molecules responsible for promoting the infi  ltration of 
leukocytes (28). IFN-γ also induces the generation of ROS 
and endoplasmic reticulum stress proteins in hepatocytes (29). 
Although mediators such as FasL have been shown to play a 
role in lymphocyte-mediated liver injury (30, 31), we show 
that NKT cell–initiated reperfusion injury is dependent on 
the production of IFN-γ. Although it is unlikely that con-
ventional CD4+ T lymphocytes release large amounts of 
IFN-γ rapidly after exposure to activating stimuli, this is a 
characteristic response of CD4+NK1.1+ NKT cells (32, 33), 
and we show that NKT cells in the liver and liver draining 
Figure 4.  Effect of NKT cell depletion or blockade on downstream 
events in reperfusion injury. WT or Rag-1 KO C57BL/6 mice were sub-
jected to 72 min of partial hepatic ischemia and 2 or 24 h of reperfusion. 
Select animals received an i.p. injection of 200 μg PK136 2 d before 
surgery, an i.p. injection of 300 μg CD1d blocking antibody 24 h before 
surgery, or ATL146e immediately after the initiation of reperfusion. 
(A) Intracellular IFN-γ production by CD3+/CD4+/CD1d-tetramer labeled 
NKT cells collected from postischemic tissue was assessed by FACS. Data 
shown are from three independent experiments (n = 9); error bars indi-
cate SEM. *, P < 0.05 versus vehicle control as assessed by one-way 
ANOVA, followed by Dunnett’s multiple comparison test. (B) Blood was 
collected by retro-orbital bleed 24 h after the initiation of reperfusion, 
and serum IFN-γ levels were measured by ELISA. Data shown are from 
three independent experiments (n = 9); error bars indicate SEM. *, P < 0.01 
versus vehicle control as assessed by one-way ANOVA, followed by 
Dunnett’s multiple comparison test. (C) Mice were killed by cervical dislo-
cation 24 h after the initiation of reperfusion, livers were perfused, and 
the left liver lobes were collected and placed immediately into 4% para-
formaldehyde fi  xative. Immunostaining of neutrophils was performed 
with rat anti–mouse neutrophil primary antibody. Data shown are from a 
single experiment representative of three independent experiments (n = 9). 
Bar, 200 μm.2644  CD1D-RESTRICTED NKT CELLS AND REPERFUSION INJURY | Lappas et al.
lymph nodes have been stimulated to produce IFN-γ by 2 h 
after the initiation of reperfusion. Moreover, the mouse liver 
contains more NKT cells than any other immune organ (14), 
and based on these considerations and the data shown in this 
study, we propose that liver reperfusion injury results from an 
infl  ammatory cascade initiated by the release of IFN-γ from 
NKT cells. This in turn may stimulate the release of TNF-α 
and other cytokines from Kupff  er cells, driving chemotaxis 
and activation of neutrophils and culminating in secondary 
liver injury (Fig. 6).
The C-type lectin receptor, NK1.1, is expressed on NKT 
cells and NK cells (34), and both cell types can be depleted 
competently by anti-NK1.1 antibodies as assessed by FACS 
analysis of splenocytes and liver leukocytes. The protective 
eff  ect of PK136, therefore, indicates that NK cells, NKT 
cells, or both are involved in tissue damage after IRI. CD1d, 
however, acts specifi  cally to prevent glycolipid antigen pre-
sentation to NKT cells (35), so the observation that the 
blockade of CD1d protects from hepatic IRI to a similar ex-
tent as does PK136 treatment indicates that NKT cells are 
the NK1.1-expressing cell type predominantly responsible for 
the induction of reperfusion injury. It is possible, however, 
that NK cells are involved in the later stages of injury, owing 
to their transactivation by NKT cell–released cytokines (36, 
37). The role of NK cells in hepatic IRI warrants further 
  investigation. Previous studies have implicated T cells in reper-
fusion injury (15–18), but a T cell– activating stimulus has 
not previously been clearly identifi  ed. Our data implicate 
CD1d-dependent antigen presentation as a key early event 
in the infl  ammatory cascade, but it is probably not the only 
stimulus. H2O2 derived from ROS is produced early during 
reperfusion and is known to facilitate activation of T cells 
Figure 5.  Inhibition by ATL146e of IFN-𝗄 production by activated 
NKT cells. (A) Purifi  ed NKT cells (200,000 per well) were incubated on 
immobilized anti-CD3 mAb in the presence of vehicle or 100 nM ATL146e. 
Supernatants were collected after 24 h, and IFN-γ concentrations were 
measured by ELISA. Data are shown as the mean ± SEM from three inde-
pendent experiments performed in triplicate. *, P < 0.01 versus vehicle 
control as assessed by an unpaired t test. (B) Bulk splenocytes (300,000 
cells per well) were incubated with 1 U/ml ADA and 1 nM-1 μM α-Gal-
Cer in the presence of 100 nM ATL146e or vehicle. *, P < 0.01 versus cor-
responding vehicle control as assessed by an unpaired t test. (C) Bulk 
splenocytes (300,000 cells per well) were incubated with 1 U/ml ADA and 
1 μM α-Gal-Cer in the presence or absence of varying concentrations of 
ATL146e ± 100 nM ZM241385 or vehicle. (D) Bulk splenocytes (300,000 
cells per well) were incubated with 1 U/ml ADA and 1 μM α-Gal-Cer in 
the presence or absence of 1 nM ATL146e ± 1 μM 8-SPT or vehicle. 
(E) Purifi  ed CD4+NK1.1+ T cells (150,000 cells per well) were incubated with 
lymphocyte- and NK cell–defi  cient splenocytes (300,000 cells per well), 
1 U/ml ADA, and 1 μM α-Gal-Cer in the presence or absence of 100 nM 
ATL146e ± 100 nM ZM241385. NK1.1-expressing cells were depleted 
from RAG-1 KO splenocytes via a FACSVantage SE Turbo Sorter. Superna-
tants were collected after 48 h, and IFN-γ concentrations were determined 
by ELISA. Data shown are from a single experiment performed in triplicate, 
representative of three independent experiments. *, P < 0.01 versus 
vehicle control as assessed by one-way ANOVA, followed by Dunnett’s 
multiple comparison test (D and E); error bars indicate SEM (A–E).JEM VOL. 203, November 27, 2006  2645
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through the oxidation of cysteine residues on protein tyro-
sine phosphatases that dephosphorylate activated TCRs (38, 
39). In addition, H2O2 directly activates NF-κB (40), result-
ing in widespread activation of infl   ammatory cells. Thus, 
NKT cell activation and ROS may collaborate to trigger 
  reperfusion injury.
The results of this study implicate NKT cells as predomi-
nant mediators of hepatic reperfusion injury that are   sensitive 
to regulation by A2AR activation. Residual injury that is 
observed after blockade of NKT activation may be due to 
damage caused in an infl  ammatory cell–independent   manner 
during the ischemic period. The majority of, but not all, mouse 
CD4+NK1.1+ NKT cells express an invariant Vα14Jα18 
TCR, and we show that these cells are activated to produce 
IFN-γ early after the initiation of reperfusion. Moreover, 
this activation is inhibited by ATL146e treatment, result-
ing in substantial protection from injury. These data suggest 
that Vα14Jα18 iNKT cells play a pivotal role in reperfusion 
injury. Nevertheless, there are CD1d-dependent mouse NKT 
cells with diverse TCRs that may also be acti  vated during 
reperfusion injury if CD1d-dependent   ligands for these cells 
are generated. Protection from iNKT cell–  mediated injury 
by A2AR activation may be relevant in humans because an 
analogous Vα24 NKT cell population exists (41), and these 
and similar cells in other mammalian   species are   activated by 
glypolipid antigens (42). It is notable that NKT cells with 
the invariant TCR are considerably less abundant in human 
than in mouse liver, and it remains to be seen whether this 
reduced cell number diminishes the contribution of iNKT 
cells to human liver IRI. Interestingly, a subpopulation of 
CD1d-reactive, non-iNKT cells has been identifi  ed in hu-
man liver (43). These intrahepatic cells are Th1 cell polarized 
and display similar activity as their invariant counterparts. It 
is feasible that if the reduced numbers of iNKT cells found 
in human liver are insuffi   cient to induce hepatic injury after 
reperfusion, the specialized subset of CD1d-restricted non-
iNKT cells may be poised to act in their stead or in addition 
to invariant cells; this possibility merits further investigation. 
Human NKT cells have been implicated in the pathophysiol-
ogy of primary biliary cirrhosis, suggesting that these cells are 
physiologically important in man (44).
The results of this work suggest a paradigm shift in the 
way we view the role of T lymphocytes in IRI. Whereas 
myeloid cells have previously been thought of as the major 
facilitators of reperfusion injury, this study indicates that the 
initiation of the reperfusion-induced infl  ammatory cascade is 
dependent on CD1d-mediated IFN-γ production by NKT 
cells. Furthermore, profound protection is imparted when 
this early event in the infl  ammatory cascade is inhibited by 
A2AR activation; through this mechanism, the release of ade-
nosine from injured tissue may serve as an endogenous regu-
lator of NKT cell activity. Therapeutic agents that inhibit the 
activity of NKT cells may therefore hold promise in the 
treatment of IRI. Clinicians have historically attempted to 
limit the by-products of reperfusion-induced infl  ammation 
via the use of neutralizing antibodies to cytokines or free rad-
ical scavengers, but it may be possible to reduce the produc-
tion of these mediators more substantially by targeting an 
upstream event in the cascade (i.e., NKT cell activation). 
The activities of ATL146e to potently inhibit the production 
of IFN-γ by CD1d-activated NKT cells and to dramatically 
protect the liver from reperfusion injury indicate that A2AR-
selective agonists may be useful tools in the treatment of IRI. 
Moreover, there is no evidence of severe toxicity evoked by 
the use of A2AR agonists as antiinfl  ammatory agents. It will 
be interesting to see if the inhibition of NKT cell activity by 
A2AR activation proves to be a clinically viable treatment for 
hepatic IRI or transplantation. It also will be of interest in fu-
ture studies to defi  ne the role of the NKT cells in reperfusion 
injury in other tissue where NKT cells are less abundant.
MATERIALS AND METHODS
Animals. WT, RAG-1 KO, and IFN-γ KO C57BL/6 mice were pur-
chased from the Jackson Laboratory. A2AR KO mice on a mixed genetic 
background were provided by J.-F. Chen (Boston University, Boston, MA). 
All animal studies were approved by the University of Virginia Animal Care 
and Use Committee.
Creating A2AR KO mice congenic to C57BL/6. The KO locus of 
B6;129P-adora2atm1chen mice with an ablated A2AR gene on a mixed genetic 
background (45) was moved onto a C57BL/6 background by monitoring 96 
microsatellites for fi  ve generations of marker-assisted breeding. In the resulting 
mouse line, DNA derived from the 129 strain can be detected only in an 
Figure 6.  Hypothetical scheme of reperfusion-induced infl  amma-
tory injury in the liver. Reperfusion results in the generation of ROS and 
H2O2, and also in the CD1d-dependent activation of NKT cells. NKT cells 
are activated to produce IFN-γ early after the initiation of reperfusion, 
and this activation is inhibited by A2AR activation. As a consequence of 
this inhibition, downstream events in the reperfusion-induced infl  amma-
tory cascade (including neutrophil accumulation and tissue necrosis) are 
considerably reduced by ATL146e treatment.2646  CD1D-RESTRICTED NKT CELLS AND REPERFUSION INJURY | Lappas et al.
8-cM region between D10Mit31 and D10Mit42 surrounding the Adora2a 
locus on chromosome 10.
NKT cell purifi  cation. WT, A2AR KO, or IFN-γ KO C57BL/6 mice 
were killed, and spleens were removed. Splenocytes were passed through 
a 40-mm nylon cell strainer (BD Biosciences) and collected in phosphate-
buff  ered saline. Red blood cells were lysed, and CD4+ T lymphocytes were 
isolated with mouse CD4 subset column kits (R&D Systems), resulting 
in >92% pure CD4+ T cells. The column-purifi  ed cells were stained for 
30 min with FITC-conjugated anti–mouse CD4 and PE-conjugated anti–
mouse NK1.1 (eBioscience) and sorted using a FACSVantage SE Turbo 
Sorter (Becton Dickinson) to produce cell populations of ≥99.8% pure 
CD4+NK1.1+ T lymphocytes.
In vitro activation of NKT cells. Cells were washed and resuspended in 
RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine 
serum and 1% antibiotic-antimycotic (Invitrogen). In vitro activation of NKT 
cells was achieved by co-culture for 48 h with splenocytes and 1 nM-1 μM 
α-Gal-Cer (KRN7000; obtained from K. Miyayama, Kirin Brewery Com-
pany, Tokyo, Japan) at 37°C in 5% CO2. Alternately, NKT cells were acti-
vated by incubation for 24 h in 96-well plates coated with 2–10 μg/ml of 
immobilized anti-CD3 mAb (BD Biosciences) at 37°C in 5% CO2. All in 
  vitro T cell activation experiments were performed with the addition of 1 U/ml 
adenosine deaminase (ADA; Roche) to remove endogenous adenosine pro-
duced by the cells that may partially activate the A2AR. For select experiments, 
cells were co-cultured with ATL146e (obtained from J. Rieger, Adenosine 
Therapeutics, Charlottesville, VA) in the presence or absence of 100 nM 
of the selective A2AR antagonist ZM241385 (Tocris) or 1 μM of the cell-
  impermeable AR antagonist 8-SPT (Research Biochemicals International).
Hepatic IRI. Mice were anesthetized by i.p. injection of 100 mg/kg ket-
amine and 10 mg/kg xylazine. Ambient temperature was controlled in the 
range of 24–26°C, and mice were placed on a heating pad at 37°C. The core 
body temperature of selected mice was monitored with a monitoring ther-
mometer (TH-8 Thermalert; Physitemp) and ranged from 35–36°C. After 
midline laparotomy, a microaneurysm clip was applied to the hepatic triad 
above the bifurcation to clamp the fl  ow of the hepatic artery, portal vein, 
and bile duct. After superfusion of the liver with warm saline, the perito-
neum was closed during 72 min of ischemia. The peritoneum was then re-
opened, and the microaneurysm clip was removed. For select experiments, 
animals received an i.p. loading dose of 1 μg/kg ATL146e or vehicle control 
immediately after the onset of reperfusion, and a primed Alzet osmotic mini-
pump was implanted i.p. 10 ng/kg/min ATL146e or vehicle was placed in 
the pumps and delivered until the experiment was terminated. The perito-
neum was sutured, and the surgical wound was closed with metal staples. 
Animals were killed by cervical dislocation at various time points after the 
initiation of reperfusion, and blood was collected via retro-orbital bleed. 
Additionally, livers were perfused, and left liver lobes were collected.
NK1.1 cell depletion and CD1d blockade. NK1.1-expressing cells were 
depleted via a single i.p. injection of 200 μg PK136 (a gift from M. Brown, 
University of Virginia, Charlottesville, VA) (46) 2 d before hepatic IRI. 
  Successful depletion was confi  rmed by FACS analysis of splenocytes and 
liver leukocytes collected at the termination of reperfusion. CD1d was 
blocked by a single i.p. injection of 300 μg of anti–mouse CD1d mAb clone 
1B1 (a gift from M. Kronenberg, La Jolla Institute for Allergy and Immuno-
logy, San Diego, CA) (47) 24 h before hepatic IRI. Anti-NK1.1 (PK136) 
and anti-CD1d (clone 1B1) were purifi  ed from hybridomas in the   University 
of Virginia hybridoma core.
Adoptive transfer of NKT cells. CD4+NK1.1+ NKT cells were purifi  ed 
from WT, A2AR KO, or IFN-γ KO C57BL/6 mice and adoptively trans-
ferred into RAG-1 KO mice via jugular vein injection 4 d before hepatic 
IRI. Successful reconstitution was confi  rmed by FACS analysis. Control ani-
mals received vehicle injections.
Serum ALT determination. After liver ischemia, blood was collected via 
retro-orbital bleed 24 h after the initiation of reperfusion. Serum ALT was 
measured with a transaminase kit according to the manufacture’s protocol 
(Pointe Scientifi  c). In brief, 20 μl of undiluted or 10×-diluted serum was 
added to 200 μl of a preheated (37°C) mix of 500 mM l-alanine and 15 mM 
α-ketoglutaric acid in a 96-well plate. The plate was placed in a spectropho-
tometer preheated to 37°C, and the absorbance at 304 nm was measured 
  every minute for 10 min. The slope of the linear portion of the change in 
absorbance over time was used to calculate IU/L of ALT.
Flow cytometry of cell surface T cell markers. Spleens were harvested, 
passed through a 40-mm nylon cell strainer (BD Biosciences) and collected in 
phosphate-buff  ered saline. Red blood cells were lysed. Alternately, livers were 
harvested, passed through a 40-μm cell strainer, and leukocyte fractions were 
isolated via Percol density gradient. Cells were washed and resuspended at 
5 × 106 cells/ml in PBS supplemented with 5% FBS and 0.1% NaN3. 0.1-ml 
aliquots were placed on ice and labeled for 30 min in the dark with anti–mouse 
CD45, anti–mouse CD3, anti–mouse CD4, anti–mouse CD8, anti–mouse 
NK1.1, anti–mouse DX5 (eBioscience), and/or α-Gal-Cer–loaded CD1d 
tetramer (National Institute of Allergy and Infectious Disease; Tetramer Facility). 
Control samples were labeled with isotype-matched control antibodies. Stained 
cells were washed with 1 ml iced PBS and resuspended in PBS containing 1% 
paraformaldehyde. The fl  uorescence intensity was measured with a dual laser 
benchtop fl  ow cytometer (FACSCalibur; Becton Dickinson) with a minimum 
of 10,000 events being collected. An excitation wavelength of 488 nm and an 
emission wavelength of 530 nm were used for FITC-stained cells; an excitation 
wavelength of 488 nm and an emission wavelength of 585 nm were used for 
PE-stained cells; an excitation wavelength of 635 nm and an emission wave-
length of 661 nm were used for APCs and Alexa 647–stained cells; and an ex-
citation wavelength of 488 nm and an emission wavelength of 670 nm were 
used for PE-Cy5.5–stained cells. Analysis was performed with FlowJo software 
(Tree Star, Inc.), and CD45+ cells were gated on for analysis.
Detection of intracellular IFN-𝗄. Intracellular IFN-γ was detected in 
liver NKT cells by FACS analysis using FIX & PERM cell permeabilization 
reagents (Caltag Laboratories) according to the manufacturer’s protocol.
Histology. Mice were killed, and livers were perfused with saline via the 
portal vein at various times after the initiation of reperfusion. Left liver 
lobes were   harvested, fi  xed in 4% paraformaldehyde in PBS, pH 7.4, and 
  embedded in   paraffi   n. 4-μm sections were subjected to standard   hematoxylin 
and eosin (H&E) staining. Necrotic area was quantifi  ed using Photoshop 
software (Adobe).
Measurement of IFN-𝗄. IFN-γ concentrations in cell culture superna-
tants or serum samples were measured by ELISA according to the manufac-
turer’s protocol (eBioscience).
Statistics. Prism software (GraphPad) was used for all statistical analyses. 
Unpaired t tests or one-way analysis of variance (ANOVA) with post-hoc 
Dunnett’s multiple comparison were used to compare experimental groups 
with a control group.
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